KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Long-Term Debt Repayments (2016 - 2024)

Ionis Pharmaceuticals (IONS) has 13 years of Long-Term Debt Repayments data on record, last reported at $44.5 million in Q4 2024.

  • For Q4 2024, Long-Term Debt Repayments changed N/A year-over-year to $44.5 million; the TTM value through Dec 2024 reached $112.3 million, up 65.65%, while the annual FY2024 figure was $44.5 million, 90.88% down from the prior year.
  • Long-Term Debt Repayments reached $44.5 million in Q4 2024 per IONS's latest filing, down from $67.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $67.8 million in Q3 2023 and bottomed at -$37000.0 in Q2 2021.
  • Average Long-Term Debt Repayments over 3 years is $41.3 million, with a median of $48.7 million recorded in 2021.